摘要
目的分析立体定向引导经皮穿刺三叉神经半月节球囊压迫术治疗原发性三叉神经痛(PTN)的临床疗效。方法51例PTN患者,根据治疗方法的不同分为观察组(26例)及对照组(25例)。观察组患者应用立体定向引导经皮穿刺三叉神经半月节球囊压迫术治疗,对照组患者实施C臂引导经皮穿刺三叉神经半月节球囊压迫术治疗。比较两组患者临床疗效、视觉模拟评分法(VAS)评分及并发症发生情况。结果观察组患者的治疗总有效率为100.00%,高于对照组的84.00%,差异有统计学意义(P<0.05)。术前,两组患者的VAS评分比较,差异无统计学意义(P>0.05);术后1 d,观察组患者的VAS评分(3.95±0.21)分明显低于对照组的(5.32±0.56)分,差异有统计学意义(P<0.05)。观察组患者的并发症发生率0低于对照组的16.00%,差异具有统计学意义(P<0.05)。结论将立体定向引导经皮穿刺三叉神经半月节球囊压迫术应用于PTN的临床治疗当中,可以获得更好的治疗效果,患者疼痛程度轻,并发症少。
Objective To analyze the clinical effect of stereotactic guided percutaneous balloon compression in the treatment of primary trigeminal neuralgia(PTN).Methods A total of 51 patients with PTN were divided into observation group(26 cases)and control group(25 cases)according to different treatment methods.The observation group was treated with stereotactic guided percutaneous balloon compression,and the control group was treated with C-arm guided percutaneous balloon compression.The clinical efficacy,visual analogue scale(VAS)scores,and occurrence of complications were compared between the two groups.Results The total effective rate of the observation group was 100.00%,which was higher than that of 84.00% of the control group,and the difference was statistically significant(P<0.05).Before surgery,there was no statistically significant difference in VAS scores between the two groups(P>0.05).1 d after surgery,the VAS score of(3.95±0.21)points in the observation group was significantly lower than that of(5.32±0.56)points in the control group,and the difference was statistically significant(P<0.05).The incidence of complications in the observation group was 0,which was lower than that of 16.00% in the control group,and the difference was statistically significant(P<0.05).Conclusion The application of stereotactic guided percutaneous balloon compression in the clinical treatment of PTN can achieve better therapeutic effect,with less pain and fewer complications.
作者
刘金阳
闫丽
谢文友
黄同亨
吴波
吴玉麟
LIU Jin-yang;YAN Li;XIE Wen-you(Yangjiang People's Hospital,Yangjiang 529500,China)
出处
《中国现代药物应用》
2023年第9期68-71,共4页
Chinese Journal of Modern Drug Application
